M. Błasińska-Morawiec

发表

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

F. Cappuzzo, W. Brugger, N. Triller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

Clinical and epidemiological analysis of basosquamous carcinoma: results of the multicenter study

M. Błasińska-Morawiec, A. Reich, W. Owczarek, 2020, Scientific Reports.

Characteristics of breast cancer patients with pathological complete response after neoadjuvant chemotherapy

M. Błasińska-Morawiec, R. Kordek, Z. Morawiec, 2010 .

Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.

M. Błasińska-Morawiec, P. Smolewski, T. Robak, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The incidence and clinical analysis of non-melanoma skin cancer

M. Błasińska-Morawiec, R. Nowicki, A. Reich, 2021, Scientific Reports.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

P. Fasching, R. Greil, R. Kreienberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.

M. Błasińska-Morawiec, N. Tubiana-Mathieu, P. Bougnoux, 2013, Breast.

Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study

J. Bonneterre, M. Campone, M. Błasińska-Morawiec, 2007, Cancer Chemotherapy and Pharmacology.

DNA damage and repair in gastric cancer--a correlation with the hOGG1 and RAD51 genes polymorphisms.

M. Błasińska-Morawiec, J. Błasiak, T. Popławski, 2006, Mutation research.

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

M. Błasińska-Morawiec, T. Robak, A. Wierzbowska, 1999, Mediators of inflammation.

A response to the ipilimumab treatment of a patient with a diagnosis of metastatic melanoma

M. Błasińska-Morawiec, M. Ułańska, A. Pękala, 2015 .

Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer

M. Campone, M. Błasińska-Morawiec, P. Koralewski, 2009, Cancer Chemotherapy and Pharmacology.

2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger

M. Błasińska-Morawiec, T. Robak, J. Blonski, 1999, Leukemia.

Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2‐chlorodeoxyadenosine (cladribine)

M. Błasińska-Morawiec, T. Robak, L. Konopka, 1997, European journal of haematology.

2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland

M. Błasińska-Morawiec, T. Robak, A. Dmoszyńska, 1999, European journal of haematology.

Pathological complete response in younger and older breast cancer patients

M. Błasińska-Morawiec, R. Kordek, W. Fendler, 2012, Archives of medical science : AMS.

Cytokines serum levels as the markers of thyroid activation in Graves' disease.

M. Błasińska-Morawiec, T. Robak, H. Stępień, 1998, Immunology letters.

prospective, randomized, multicenter trial first-line therapy in chronic lymphocytic leukemia: report of a Cladribine with prednisone versus chlorambucil with prednisone as

M. Błasińska-Morawiec, A. Dmoszyńska, A. Skotnicki, 2013 .

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

M. Błasińska-Morawiec, T. Robak, A. Dmoszyńska, 2000, Blood.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The DNA-damaging potential of tamoxifen in breast cancer and normal cells

M. Błasińska-Morawiec, J. Błasiak, Z. Morawiec, 2007, Archives of Toxicology.

Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer

M. Błasińska-Morawiec, P. Potemski, J. Szemraj, 2012, Molecular Biology Reports.

The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations

A. Jakubowska, J. Lubiński, M. Błasińska-Morawiec, 2022, British Journal of Cancer.

Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.

M. Błasińska-Morawiec, T. Robak, A. Hellmann, 1997, Leukemia & lymphoma.

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.

J. Zaucha, M. Błasińska-Morawiec, T. Robak, 1996, Leukemia & lymphoma.

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

M. Krzakowski, J. Jassem, E. Tan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

P. Rutkowski, M. Błasińska-Morawiec, R. Herbst, 2019, The British journal of dermatology.

A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.

M. Błasińska-Morawiec, J. Rolski, Miguel Martín, 2009, Clinical breast cancer.

Vaginal bleeding as a first symptom of malignant lymphoma: case reports, diagnosis and successful treatment.

M. Błasińska-Morawiec, J. Sobotkowski, I. Dowgier-Witczak, 2004, European journal of gynaecological oncology.

Primary B-cell lymphoma of the uterine corpus – case report and review of the literature

M. Błasińska-Morawiec, R. Kordek, L. Gottwald, 2008 .

2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.

M. Błasińska-Morawiec, T. Robak, A. Dmoszyńska, 1999, Leukemia & lymphoma.

Prognostic value of expression of intracellular and extracellular domains of HER2 in patients with HER2-possitive breast cancer

M. Błasińska-Morawiec, A. Kulig, P. Potemski, 2011 .

Correlation between breast cancer receptor subtypes and nodal remission

M. Błasińska-Morawiec, R. Kordek, Z. Morawiec, 2012 .

2‐Chlorodeoxyadenosine (cladribine)‐related eosinophilia in patients with lymphoproliferative diseases

M. Błasińska-Morawiec, T. Robak, Z. Kuratowska, 1997, European journal of haematology.

The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia.

J. Roliński, M. Błasińska-Morawiec, T. Robak, 1997, European journal of cancer.

Annals of Oncology

M. Krzakowski, J. Jassem, E. Tan, 2022 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS.

E. Espinosa, M. Benasso, M. Błasińska-Morawiec, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC.

F. Cappuzzo, W. Brugger, N. Triller, 2009, Journal of Clinical Oncology.

Survival from breast cancer in women with a BRCA2 mutation by treatment

F. Couch, P. Møller, W. Foulkes, 2021, British Journal of Cancer.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Single‐Agent Oral Vinorelbine as First‐Line Chemotherapy for Endocrine‐Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST‐228 Phase II Study

E. Espinosa, M. Błasińska-Morawiec, G. Steger, 2017, Clinical breast cancer.

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

F. Cappuzzo, W. Brugger, N. Triller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer

M. Błasińska-Morawiec, P. Potemski, J. Szemraj, 2012, Molecular Biology Reports.